Tiprelestat for COVID-19: real-time analysis

Download Image

Post

c19early.org

Tiprelestat for COVID-19

1 study with 17 patients

Serious outcome risk

Tiprelestat

Control

COVID-19 Tiprelestat studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−189%

Mortality (1)−189%

RCTs (1)−189%

Late (1)−189%

00.511.5+

← Tiprelestat
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Tiprelestat is a recombinant human elafin protein administered intravenously that acts as an anti-inflammatory agent through reversible inhibition of neutrophil elastase and proteinase 3, aiming to attenuate neutrophil-driven lung injury in severe COVID-19. Recent:

Bergs.


Sep 16 2025	Bergs et al., Advances in Therapy, doi:10.1007/s12325-025-03362-w	Tiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trial
Sep 16 2025	189% higher mortality (p=1), 11% lower progression (p=1), 22% shorter ICU admission (p=0.85), and 40% lower need for oxygen therapy (p=0.52). RCT 17 hospitalized COVID-19 patients showing no significant differences with tiprelestat (recombinant human elafin, a neutrophil elastase inhibitor). There was a trend toward benefit for oxygen support.